US Patent 9,597,397: Bendamustine Rapid-Infusion Claims, Scope and Patent Landscape
US Patent 9,597,397 protects a specific method of administering bendamustine for cancer treatment. Its core subject is a low-volume, rapid parenteral infusion using a formulation containing bendamustine, polyethylene glycol, propylene glycol and a parenterally acceptable diluent.
The patent does not claim bendamustine generally. It does not cover every bendamustine formulation or every intravenous administration method. Its principal commercial relevance is to Bendeka-like products using a short infusion time, approximately 50 mL of formulation and the specified PEG/propylene glycol excipient system.
What does US Patent 9,597,397 protect?
Claim 1 requires all of the following elements:
| Claim element |
Requirement |
| Therapeutic use |
Treatment of cancer or malignant disease |
| Route |
Parenteral administration |
| Administration time |
About 15 minutes or less |
| Administration volume |
About 100 mL or less |
| Bendamustine concentration |
0.96-5.59 mg/mL |
| Nonaqueous component |
3.8-22.4 vol% |
| Nonaqueous ingredients |
Polyethylene glycol and propylene glycol |
| Other ingredients |
Parenterally acceptable diluent |
| Antioxidant |
Optional |
The claim uses "comprising," which generally makes it open-ended. A competing product may contain additional excipients and still fall within the claim if it contains every required element.
The numerical terms are qualified by "about." That language creates potential claim-construction issues at the boundaries, but it does not make the concentration, volume or administration-time limitations irrelevant. A product materially outside those ranges may avoid literal infringement, subject to the doctrine of equivalents.
How do claims 1 through 7 differ?
| Claim |
Scope |
Commercial significance |
| 1 |
Broadest independent method claim covering rapid parenteral administration of the specified bendamustine formulation |
Principal infringement claim |
| 2 |
Claim 1 where the subject is human |
Relevant to human oncology products |
| 3 |
Claim 1 where administration occurs in about 10 minutes |
Closely tracks a rapid Bendeka administration protocol |
| 4 |
Claim 1 using about 50 mL of composition |
Targets low-volume administration |
| 5 |
Claim 1 where the polyethylene glycol is PEG 400 |
Narrows the excipient identity |
| 6 |
Claim 1 with a PEG-to-propylene-glycol weight ratio of about 90:10 |
Narrows formulation composition |
| 7 |
Claim 1 with monothioglycerol as the antioxidant |
Targets a specific stabilizer |
Claims 2 through 7 depend on claim 1. A product must satisfy claim 1 before it can infringe any dependent claim.
Claim 3 has particular commercial importance because a 10-minute administration is a recognizable feature of rapid bendamustine products. Claims 4 through 7 provide narrower fallback positions if claim 1 is limited or a competing product avoids one of its broader elements.
What formulation is covered by US 9,597,397?
The claimed formulation contains:
- bendamustine or a pharmaceutically acceptable salt;
- polyethylene glycol;
- propylene glycol;
- a parenterally acceptable diluent; and
- optionally, an antioxidant.
The dependent claims identify PEG 400, a roughly 90:10 PEG-to-propylene-glycol weight ratio and monothioglycerol.
The relevant formulation is likely the composition administered to the patient rather than merely the contents of an undiluted manufacturing vessel. A concentrated vial may not satisfy the claim if the claimed concentration and volume are assessed after dilution. The infringement analysis must identify the point at which the claimed composition is measured.
Potential outcomes include:
- A stock solution falls outside the claimed concentration range.
- The diluted infusion falls inside the claimed range.
- The final administered composition satisfies the volume and time limitations.
- A different antioxidant avoids claim 7 but not claim 1.
- A different PEG-to-propylene-glycol ratio avoids claim 6 but not claim 1.
When does US Patent 9,597,397 expire?
The patent has a projected base expiration date of July 15, 2034, based on the U.S. nonprovisional filing date and the 20-year patent-term framework. The actual enforceable date depends on the patent-term-adjustment calculation recorded by the USPTO. [1]
| Event |
Date |
| Earliest claimed priority |
July 15, 2013 |
| U.S. nonprovisional filing |
July 15, 2014 |
| Patent grant |
March 21, 2017 |
| Projected base expiration |
July 15, 2034 |
The provisional priority date does not ordinarily start the 20-year term. The relevant term generally runs from the earliest effective U.S. nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. [2]
What is the Orange Book status of bendamustine rapid-infusion products?
FDA-approved bendamustine products include Treanda and Bendeka. Bendeka is associated with Eagle Pharmaceuticals and uses a lower-volume, shorter-duration administration protocol. FDA labeling describes dilution and administration over approximately 10 minutes, which corresponds closely to the subject matter of claims 3 and 4. [3]
The Orange Book analysis must distinguish among:
- active-ingredient patents;
- formulation patents;
- method-of-use patents;
- patents listed against a specific NDA; and
- patents that may be asserted in ANDA litigation.
US 9,597,397 is a method patent. Its listing or enforceability does not mean that every generic bendamustine product infringes. Infringement depends on the proposed formulation, labeling, administration instructions and actual use.
A generic applicant may submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable or not infringed. If the NDA holder or patent owner files a timely infringement action, the filing may trigger a statutory 30-month stay of approval under the Hatch-Waxman framework. [4]
What Paragraph IV challenges and generic entry risks exist?
The highest-risk generic would copy the Bendeka administration profile and instruct healthcare providers to administer bendamustine:
- parenterally;
- in 15 minutes or less;
- in 100 mL or less;
- at a concentration within the claimed range; and
- in a formulation containing PEG and propylene glycol.
A product using a 10-minute administration in approximately 50 mL would present the clearest claim-matching risk.
Potential design-around strategies include:
| Strategy |
Potential effect |
| Use a longer infusion time |
May avoid the administration-time limitation |
| Use a volume above 100 mL |
May avoid claim 1 |
| Use a formulation without PEG or propylene glycol |
May remove required claim elements |
| Change the bendamustine concentration |
May avoid the stated concentration range |
| Use a different excipient system |
May avoid claim 1 and dependent claims |
| Use a different antioxidant |
May avoid claim 7 |
| Omit rapid-infusion instructions |
May reduce inducement exposure |
| Use a non-infringing label carve-out |
May limit method-of-use exposure |
A label carve-out is not automatically conclusive. If the manufacturer promotes the patented administration method or encourages use that satisfies the claims, induced-infringement theories may remain relevant under 35 U.S.C. § 271(b). The filing of an ANDA can create an artificial act of infringement under § 271(e)(2). [5]
How strong is the patent estate for Bendeka?
The strength of US 9,597,397 comes from the alignment between its claim limitations and the commercial administration profile of Bendeka.
Strengths
- Claim 1 combines formulation and administration limitations.
- Claims 3 and 4 track commercially recognizable 10-minute and 50 mL protocols.
- The patent protects a delivery system rather than only the active ingredient.
- The open "comprising" language permits additional excipients.
- A close Bendeka copy could satisfy multiple claims simultaneously.
Weaknesses
- Every limitation of claim 1 must be established.
- The patent does not cover bendamustine products using unrelated excipient systems.
- It does not automatically cover non-parenteral products.
- A generic may avoid infringement through a different infusion time, volume or concentration.
- The "about" limitations may create disputes over numerical boundaries.
- Method claims depend heavily on the approved label and actual administration practice.
The patent is strongest against a close formulation and labeling copy. It is weaker against a materially redesigned product.
What patent landscape surrounds bendamustine?
The bendamustine landscape has several layers.
Active-ingredient and early composition patents
Earlier bendamustine patents concern the active compound, chemical forms or broad pharmaceutical compositions. Their commercial significance differs from US 9,597,397 because they do not necessarily protect the later low-volume, rapid-infusion protocol.
Formulation patents
US 9,597,397 is a formulation-linked method patent. It combines PEG and propylene glycol in specified ranges with a rapid parenteral administration protocol. Formulation patents can remain commercially important after active-ingredient patent rights have expired.
Method-of-use patents
The patent claims treatment of cancer or malignant disease, but the principal limitation concerns how the drug is administered. It is therefore a hybrid formulation and method-of-use patent. A competing product may have the same active ingredient and indication while avoiding infringement through a materially different formulation or administration method.
Manufacturing and supply-chain barriers
The claims provided do not expressly cover a manufacturing process. The patent therefore does not independently prohibit production using a different process. Separate risks may arise from process patents, trade secrets, stability data, regulatory requirements or supplier controls.
What patent litigation and settlements affect generic launch?
The issued claims alone do not establish whether a particular Paragraph IV notice, district court action or settlement exists. The decisive commercial questions are:
- Whether US 9,597,397 was listed against the relevant Bendeka NDA.
- Whether an ANDA applicant filed a Paragraph IV certification.
- Whether the patent owner filed an infringement action within the statutory period.
- Whether a 30-month stay was triggered.
- Whether the parties entered an early-launch or license settlement.
- Whether the settlement includes a license, authorized-generic arrangement or formulation restrictions.
- Whether any final judgment addressed claim construction, validity or infringement.
A settlement could allow an earlier launch without invalidating the patent. The absence of a reported settlement would not itself establish that no challenge exists.
How does US 9,597,397 compare with a conventional bendamustine patent?
| Issue |
US 9,597,397 |
Conventional active-ingredient patent |
| Protected subject |
Administration method using a defined formulation |
Chemical compound or broad composition |
| Route |
Parenteral |
May be route-neutral |
| Key limitation |
Rapid, low-volume infusion |
Use of bendamustine itself |
| Design-around potential |
Relatively substantial |
Often lower before expiry |
| Dependence on label |
High |
Variable |
| Exposure to Bendeka-like copy |
High |
Depends on patent status |
| Relevance to oral or non-parenteral products |
Limited |
Potentially broader |
What is the likely generic launch scenario?
The most exposed product would copy Bendeka's formulation and labeling, including a 10-minute administration in approximately 50 mL. That product would face the highest risk under claims 1, 3, 4, 5, 6 and 7.
A second scenario involves a formulation copy with modified administration instructions. That approach may avoid some method-of-use exposure, although actual prescribing, promotion and induced-use theories could remain relevant.
The lowest-risk scenario involves a different excipient system, a longer infusion, a larger dilution volume or a concentration outside the claimed range. That product may still face separate regulatory and patent issues, but its exposure to US 9,597,397 would be materially reduced.
Key Takeaways
- US 9,597,397 is a method patent focused on rapid, low-volume parenteral bendamustine administration.
- Claim 1 requires the formulation and administration conditions to occur together.
- Claims 3 and 4 closely track a 10-minute administration in approximately 50 mL.
- Claims 5 through 7 narrow the patent to PEG 400, a roughly 90:10 PEG-to-propylene-glycol ratio and monothioglycerol.
- The projected base expiration date is July 15, 2034, subject to recorded patent-term adjustments.
- The strongest infringement risk is for a Bendeka-like generic using the same excipients, concentration range, volume and infusion time.
- A generic may pursue a formulation, volume, concentration or administration-time design-around.
- Paragraph IV risk depends on the current Orange Book listing, ANDA certification and litigation record, not solely on the issued claims.
Frequently Asked Questions
Does US 9,597,397 cover all bendamustine injections?
No. The claims require specified excipients, concentration ranges, parenteral administration and rapid, low-volume delivery.
Can a generic avoid the patent by using a different antioxidant?
Possibly. A different antioxidant may avoid claim 7, but it will not avoid claim 1 if all claim 1 elements remain present.
Does the patent cover a 10-minute infusion in 100 mL?
Potentially, if the composition satisfies claim 1. Claim 3 covers about 10 minutes, while claim 4 narrows the volume to about 50 mL.
Is bendamustine itself protected by this patent?
No. US 9,597,397 does not claim bendamustine as a chemical compound. It claims a treatment method using a defined formulation and administration protocol.
Can a generic receive FDA approval before the patent expires?
Yes, depending on the patent certification, litigation outcome, regulatory exclusivity and any settlement or license terms. FDA approval timing and commercial launch timing are separate issues.
References
-
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,597,397, Bendamustine formulations and methods of use thereof.
-
35 U.S.C. §§ 154, 156, 271, 282 (2023).
-
U.S. Food and Drug Administration. (2023). Bendeka (bendamustine hydrochloride) injection prescribing information. Eagle Pharmaceuticals, Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. Center for Drug Evaluation and Research.
